KIF2C and Familial prostate cancer: We selected the mitotic centromere-associated kinesin (MCAK) as a target in prostate cancer because it was novel and there was marked overexpression of the MCAK gene (P = 1.55×10−15) in localized CRPC from the MD Anderson Cancer Center dataset as compared to hormone sensitive prostate cancer cases (n = 108) from the Memorial Sloan Kettering Cancer Center dataset (GSE 21032).